ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TRIB Trinity Biotech PLC

1.81
0.06 (3.43%)
Pre Market
Last Updated: 13:32:58
Delayed by 15 minutes
Name Symbol Market Type
Trinity Biotech PLC NASDAQ:TRIB NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.06 3.43% 1.81 1.72 2.50 443 13:32:58

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2017 Financial Results

03/07/2017 12:57pm

GlobeNewswire Inc.


Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Trinity Biotech Charts.

Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2017 on Thursday, July 20, 2017. The Company has scheduled a conference call for that same day, Thursday, July 20, 2017 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:

 USA: 1-844-861-5499
 International: 1-412-317-6581
 Conference ID #:10110132

A simultaneous webcast of the call can be accessed at:https://www.webcaster4.com/Webcast/Page/1135/21731

A replay of the call can be accessed until July 27, 2017 by dialing:

 USA: 1-877-344-7529
 International: 1-412-317-0088
 Conference ID #: 110110132

The webcast of the call will be available for 30 days at:https://www.webcaster4.com/Webcast/Page/1135/21731

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Contact:
Trinity Biotech plc
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com

Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700

1 Year Trinity Biotech Chart

1 Year Trinity Biotech Chart

1 Month Trinity Biotech Chart

1 Month Trinity Biotech Chart

Your Recent History

Delayed Upgrade Clock